EstechPharma Co. Ltd (041910) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of EstechPharma Co. Ltd stock KRW 5,810, price KRW 5,220, upside +11.3%, quality 57 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 4,300 KRW – 12,599 KRW · fair‑value band 4,793 KRW – 7,462 KRW · the 5,220 KRW price screens below the 5,810 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow EstechPharma Co. in your weekly email
Every Wednesday you see whether EstechPharma Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EstechPharma Co., Ltd. manufactures and sells pharmaceuticals products. It also offers raw materials, such as RBM and PLK. The company was formerly known as Estech Chemical and changed its name to EstechPharma Co., Ltd. in January 2001.
Show moreShow less
EstechPharma Co., Ltd. was founded in 1996 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
EstechPharma Co. Ltd (041910) currently trades at 5,220 KRW, while our model-based Fair Value estimate is 5,810 KRW, implying the stock looks roughly 10% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 8,765 KRW per share, and 13 of the 24 models we run sit above the 5,220 KRW price.
Bear case: the Dividend Discount group reads lowest at 796.24 KRW, and 11 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 4,793 KRW (bear) to 7,462 KRW (bull), the price of 5,220 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
EstechPharma Co. Ltd reported revenue of 55.5B KRW in FY2025 versus 60.4B KRW in FY2021, a compound −2.1%/yr. Reported net income was 6.2B KRW in FY2025, compounding −2.7%/yr from FY2021.
Key figures
Market cap 75.1B KRW (≈ $56.0M) Micro · P/S ratio 1.17 · Dividend yield 1.6% · Net margin 1.6% · Return on equity 482% · Return on assets (EBIT) 2.4% (5-year average) · Operating margin 4.9% · Revenue (TTM) 63.9B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −14% fair-value upside, at 11%, 041910 screens cheaper than that median.
Fair Value models
Bear4,793 KRWFair Value 5,810 KRWBull7,462 KRW
Price 5,220 KRW · Upside +11.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Start year 2020 (pandemic). Over 10 years: +2.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−6.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.8%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−13.1% vs 2.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −0.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+11.3% · Above median
Profitability
Return on equity (12 months)482.4% · Top 25%
Return on assets3.1% · Above median
Net margin (12 months)1.6% · Below median
Operating margin (12 months)4.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Below median
Dividend yield (12 months)1.6% · Above median
Balance sheet
Debt / equity0.22× · Highest 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/B0.55× · Cheapest 25%
P/S (12 months)1.17× · Cheaper than median
Price / free cash flow (fiscal year)9.1× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is EstechPharma Co. Ltd (041910) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 5,810 KRW versus a price of 5,220 KRW, about +11% upside (undervalued).
What is the fair value of 041910?
Our model-based fair value for EstechPharma Co. Ltd is 5,810 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 5,220 KRW.
What is the quality score of 041910?
EstechPharma Co. Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EstechPharma Co. Ltd (041910)?
Our model-based price target is the fair value of 5,810 KRW (as of Nov 9, 2026) from 24 valuation models. Cautious scenario 4,793 KRW, optimistic scenario 7,462 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the EstechPharma Co. Ltd stock forecast for 2026?
Our models put fair value at 5,810 KRW, about +11% upside versus a price of 5,220 KRW (undervalued). Cautious scenario 4,793 KRW, optimistic scenario 7,462 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of EstechPharma Co. Ltd (041910)?
EstechPharma Co. Ltd reported trailing-twelve-month revenue of about 63.9B KRW (latest available figure, as of Nov 9, 2026).
Does EstechPharma Co. Ltd pay a dividend?
EstechPharma Co. Ltd currently shows a dividend yield of 1.56% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of EstechPharma Co. Ltd (041910)?
EstechPharma Co. Ltd has a dividend yield of 1.6%.
What growth is priced into EstechPharma Co. Ltd (041910)?
For today's price to be fair in a discounted-cash-flow model, EstechPharma Co. Ltd would have to grow free cash flow by +1.7 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.0 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 041910 use?
Our models discount EstechPharma Co. Ltd at 13.5 %: a base by market capitalisation (micro), damped by beta 1.10, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EstechPharma Co. Ltd that is +1.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has EstechPharma Co. Ltd (041910) delivered so far?
Over the past 5 years revenue at EstechPharma Co. Ltd grew -2.0 % a year. The price currently implies free-cash-flow growth of +1.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EstechPharma Co. Ltd (041910) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into EstechPharma Co. Ltd (+1.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EstechPharma Co. Ltd (041910)?
The free-cash-flow yield on the price is 11.94 %: that much free cash flow EstechPharma Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EstechPharma Co. Ltd (041910)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EstechPharma Co. Ltd it is 5,810 KRW per share (as of Nov 9, 2026), against a price of 5,220 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is EstechPharma Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 041910 trades below its calculated fair value: price 5,220 KRW, fair value 5,810 KRW, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 041910?
No. The price is what the market pays today (5,220 KRW); the fair value is what the company's own numbers justify (5,810 KRW). For EstechPharma Co. Ltd the two are 590.43 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is EstechPharma Co. Ltd worth?
The market values EstechPharma Co. Ltd at about 75.1B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 5,220 KRW; our models calculate a fair value of 5,810 KRW per share.
What do the bullish and bearish scenarios say about 041910?
Our models span a range for EstechPharma Co. Ltd: cautious scenario 4,793 KRW, base 5,810 KRW, optimistic 7,462 KRW per share (as of Nov 9, 2026, price 5,220 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EstechPharma Co. Ltd (041910)?
Balance-sheet figures for EstechPharma Co. Ltd (as of Nov 9, 2026): return on equity 482.4%, debt of 0.22 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 041910 from its 52-week high?
EstechPharma Co. Ltd trades at 5,220 KRW, about 41% below its 52-week high of 8,920 KRW and 21% above the low of 4,300 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 5,810 KRW is for.
Which stocks are comparable to EstechPharma Co. Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EstechPharma Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 5,220 KRW, calculated fair value 5,810 KRW (+11%), Quality Score 57/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 041910 calculated?
We run EstechPharma Co. Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,810 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. EstechPharma Co. Ltd currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EstechPharma Co. Ltd (041910)?
The closing price on Nov 10, 2026 was 5,220 KRW. Our model-based fair value is 5,810 KRW, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EstechPharma Co. Ltd right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of EstechPharma Co. Ltd
How large is the market capitalisation of EstechPharma Co. Ltd (041910)?
The market capitalisation of EstechPharma Co. Ltd is 75.1B KRW (≈ $56.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EstechPharma Co. Ltd (041910)?
The price-to-sales ratio of EstechPharma Co. Ltd is 1.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of EstechPharma Co. Ltd (041910)?
The dividend yield of EstechPharma Co. Ltd is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EstechPharma Co. Ltd (041910)?
The net margin of EstechPharma Co. Ltd is 1.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EstechPharma Co. Ltd (041910)?
The return on equity (ROE) of EstechPharma Co. Ltd is 482% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EstechPharma Co. Ltd (041910)?
On an EBIT basis the return on assets of EstechPharma Co. Ltd is 2.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EstechPharma Co. Ltd (041910)?
The operating margin of EstechPharma Co. Ltd is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at EstechPharma Co. Ltd (041910)?
Earnings per share at EstechPharma Co. Ltd are growing −43.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does EstechPharma Co. Ltd (041910) carry?
The net debt of EstechPharma Co. Ltd is 23.2B KRW (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch EstechPharma Co. Ltd in the live analysis
One click puts EstechPharma Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026